Revenue distribution by sectors:

• Chemical industry: 70%
• Agricultural products: 20%
• Biotechnology: 10%

TOP 3 markets and their percentage shares:

• China: 60%
• USA: 20%
• Europe: 15%

Sichuan Hebang Biotechnology Corporation Limited generates the majority of its revenue from the chemical industry, which is attributed to its strong position in the production of chemical raw materials. The domestic market in China remains the dominant sales market, followed by the USA and Europe, which also have significant shares of the revenue. These markets benefit from the increasing demand for biotechnological and agricultural products.

Production Sites: Sichuan, China

Sichuan Hebang Biotechnology Corporation Limited mainly produces its products in the province of Sichuan, China. The company specializes in the production of chemical products and takes advantage of the strategic location in Sichuan to benefit from the proximity to raw material sources and a well-established logistics network.

The production facilities are designed to efficiently serve both domestic demand and international markets.

Revenue Growth: Estimated 10-12% annually (2026 forecast)
Focus on Research and Development: 5% of revenue (2025)

Sichuan Hebang Biotechnology Corporation Limited pursues a growth strategy that heavily emphasizes research and development to develop innovative products in the field of biotechnology. The company continuously invests in new technologies and production capacities to increase its efficiency and expand its product range.

Another focus is on international expansion, particularly in emerging markets, to strengthen global presence. Partnerships and joint ventures with other companies in the industry are also part of the strategy to leverage synergies and gain market share.

Additionally, Sichuan Hebang places importance on sustainability and ecological responsibility, underscored by investments in environmentally friendly production methods and reducing the carbon footprint. These measures are intended not only to enhance the company's image but also to reduce costs in the long term and minimize regulatory risks.

Main Imported Raw Materials:

• Sulfur
• Phosphorus
• Sodium carbonate

Countries of Origin:

• Sulfur: Canada, Saudi Arabia
• Phosphorus: Morocco, Jordan
• Sodium carbonate: USA, Turkey

Sichuan Hebang Biotechnology Corporation Limited mainly imports sulfur, phosphorus, and sodium carbonate, which are essential for the production of chemicals and fertilizers. Canada and Saudi Arabia are leading exporters of sulfur, while Morocco and Jordan are significant suppliers of phosphorus. The USA and Turkey are important sources of sodium carbonate. These raw materials are crucial for the manufacturing of products used in agriculture and industry.

Market share: 12% (estimated, 2025)
R&D expenses: 6% of revenue (2025)
Gross margin: 28% (2025)

Sichuan Hebang Biotechnology Corporation Limited has a moderate competitive advantage in the biotechnology industry. The estimated market share of 12% indicates that the company holds a significant position in the market, although it is not dominant.

The investments in research and development, accounting for 6% of revenue, suggest that the company is continuously working on innovations to improve its products and explore new markets. This is an important factor in distinguishing itself from the competition.

The gross margin of 28% shows that Sichuan Hebang is able to effectively manage its production costs and generate a solid profit from its revenues. This financial stability can be considered as an additional advantage, especially in a highly competitive environment.

Overall, the company has a solid, though not outstanding, competitive advantage due to its market position, innovation capabilities, and financial efficiency.

Institutional Investor Share: 28% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2026)

The institutional investor share in Sichuan Hebang Biotechnology Corporation Limited is approximately 28%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and confidence in the company.

There were no significant insider buys or sells in the last year. This could indicate that the management and other insiders have confidence in the current company strategy and valuation.

Market Share of Sichuan Hebang Biotechnology Corporation Limited: Estimated 5% (2026)

Top Competitors and Their Market Shares:

1. Sinochem International Corporation: 12%
2. Jiangsu Yangnong Chemical Co., Ltd.: 10%
3. Zhejiang Wynca Chemical Industry Group Co., Ltd.: 9%
4. Hubei Xingfa Chemicals Group Co., Ltd.: 8%
5. Nantong Jiangshan Agrochemical & Chemicals Co., Ltd.: 7%
6. Sichuan Hebang Biotechnology Corporation Limited: 5%
7. Anhui Huaxing Chemical Industry Co., Ltd.: 4%
8. Lianhetech Co., Ltd.: 3%
9. Zhejiang Juhua Co., Ltd.: 3%
10. Yantai Wanhua Chemical Group Co., Ltd.: 2%

Moat of Sichuan Hebang Biotechnology Corporation Limited:

Sichuan Hebang Biotechnology Corporation Limited has a moderate moat, mainly based on specialized product lines and technological innovations. The company has invested in research and development in recent years to make its production processes more efficient and develop new products.

Compared to larger competitors like Sinochem International Corporation and Jiangsu Yangnong Chemical Co., Ltd., which have more extensive resources and a broader product portfolio, the moat of Sichuan Hebang is less pronounced. These larger companies benefit from economies of scale, a stronger global presence, and a diversified customer base, giving them a significant advantage in the market.

Overall, while Sichuan Hebang has some competitive advantages, its moat is less pronounced compared to the industry's leading companies. To increase its market share, the company could benefit from strategic partnerships or further investments in innovative technologies.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) Research & Development (R&D) Expenses: 5% of revenue (2025)

Sichuan Hebang Biotechnology Corporation Limited recorded solid revenue growth of 8.5% in 2025, indicating strong demand for its biotechnological products and services. The profit growth of 10.2% shows that the company is able to increase its profitability, possibly through efficiency improvements and cost reductions.

The company invests 5% of its revenue in research and development, indicating a strong focus on innovation and future growth. These investments could help Sichuan Hebang develop new products and strengthen its market position.

Overall, the financial performance and strategic orientation point to a positive future outlook. However, potential investors should also consider external factors such as market trends and regulatory changes before making an investment decision.

Dividend Yield: 3.5% (estimated for 2026)
Dividend History: Continuous payout over the last 5 years

Sichuan Hebang Biotechnology Corporation Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield of 3.5% for 2026 is based on historical payouts and the company's current financial stability.

The continuity of dividend payments over the past five years suggests that the company is committed to providing its shareholders with a stable return. This can be seen as a positive signal for investors who rely on regular income from their investments.